The PREVENT Dementia study at Trinity College Dublin
The PREVENT study aims to establish novel and clinically applicable early biomarkers of Alzheimer’s disease, 20 to 40 years prior to its clinical diagnosis. The Prevent study at TCD is part of a large-scale multi-centre study carried out in collaboration with Cambridge, Oxford, Edinburgh universities, Imperial College London in the UK and the INSERM Neuroscience, in France. It is designed in response to the pandemic of dementia – projected to increase from 46.8 million in 2015 to 131.5 million in 2050. Present drug treatments have limited ability to stop or even delay cognitive decline.
Recent studies suggest that biological, cognitive and emotional changes can already be seen in high-risk individuals many years before diagnosis. The early biomarkers of Alzheimer’s disease that this study will develop will serve as essential prerequisites to future, population-wide early intervention programs, both pharmaceutical and environmental. Therefore, this work has tremendous potential to improve early detection, treatment and ultimately lead to the prevention of Alzheimer’s dementia.
Benefits of participation
- Contribute in identifying early signs/risks of Alzheimer’s disease.
- Participants will receive a full medical and neurological check.
- Participants can challenge themselves in enjoyable cognitive assessments.
- There will be no disclosure of personal information or risks for Alzheimer’s disease.
- 40-59 years old
- Absence of dementia/cognitive impairments
- With/without parents diagnosed with dementia
- No contraindications for MRI (e.g. metal implants or claustrophobia)
In the first year, eligible participants will be asked to participate in two sessions of assessments (below). All tests will be repeated and participants monitored for changes two years later.
The first session at St. James’s Hospital, Dublin will include
- Biological samples including blood, saliva, urine, and spinal fluid (optional) will be collected.
- Neurological examination
- Lifestyle interview: Self-report
The second session will include an
- 80-minute MRI scan
There will not be any disclosure of personal information or risks for Alzheimer’s disease.